Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
AstraZeneca
Citi
UBS
Harvard Business School
Fuji

Generated: April 23, 2019

DrugPatentWatch Database Preview

PF PRISM CV Company Profile

« Back to Dashboard

Summary for PF PRISM CV
International Patents:995
US Patents:44
Tradenames:13
Ingredients:12
NDAs:17

Drugs and US Patents for PF PRISM CV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes 8,372,995 ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-003 Oct 27, 2017 RX Yes No 7,919,625 ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-007 Dec 30, 2004 RX Yes No 6,001,876*PED ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-004 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No 10,022,447*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for PF PRISM CV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-001 Aug 25, 2000 5,308,847*PED ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 5,567,817 ➤ Try a Free Trial
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-001 Aug 25, 2000 5,989,591*PED ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002 5,567,817 ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002 5,364,938 ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 5,116,844 ➤ Try a Free Trial
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 5,134,127 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PF PRISM CV drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2012-02-29
➤ Subscribe Tablets 100mg and 500mg ➤ Subscribe 2016-09-06
➤ Subscribe Capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg ➤ Subscribe 2008-12-30
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-05-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2008-09-12
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2010-10-08
➤ Subscribe Injection 25 mg/mL, 1.8 mL vial ➤ Subscribe 2011-05-25
➤ Subscribe Tablets 0.5 mg ➤ Subscribe 2010-08-25
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2015-05-08
➤ Subscribe Tablets 400 mg ➤ Subscribe 2018-10-15
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2010-05-19
➤ Subscribe Tablets 1 mg and 5 mg ➤ Subscribe 2018-02-23
➤ Subscribe Tablets 50 mg and 200 mg ➤ Subscribe 2008-04-14
➤ Subscribe For Injection 50 mg per vial ➤ Subscribe 2009-06-15
➤ Subscribe Tablets 1 mg and 2 mg ➤ Subscribe 2009-12-17

Supplementary Protection Certificates for PF PRISM CV Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1666481 300887 Netherlands ➤ Try a Free Trial PRODUCT NAME: TOFACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TOFACITINIBCITRAAT; REGISTRATION NO/DATE: EU/1/17/1178 20170324
1044189 PA2008010,C1044189 Lithuania ➤ Try a Free Trial PRODUCT NAME: VARENICLINUM TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001 - EU/1/06/360/010, 0060926
1218348 1390007-1 Sweden ➤ Try a Free Trial PRODUCT NAME: AXITINIB, VALFRITT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT; REG. NO/DATE: EU/1/12/777/001 20120903
1044189 122008000038 Germany ➤ Try a Free Trial PRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926
1044189 325 Finland ➤ Try a Free Trial
1902029 C20140016 00110 Estonia ➤ Try a Free Trial PRODUCT NAME: BOSUTINIIB;REG NO/DATE: K(2013)1968 (LOPLIK) 02.04.2013
1666481 1790038-2 Sweden ➤ Try a Free Trial PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REG. NO/DATE: EU/1/17/1178 20170324
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Medtronic
Queensland Health
Federal Trade Commission
Cipla
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.